#muscle atrophy

• Amyosthenia — A functional structural deficiency characterized by pronounced muscle weakness or lack of strength within the skeletal muscles. This pathological condition can be caused by muscle atrophy, metabolic disorders, malnutrition, or prolonged periods of physical immobilization.
• Amyotrophic — Pertaining to amyotrophy or causing progressive loss of muscle mass; characterized by the atrophy of skeletal muscles due to denervation or a neurodegenerative disease. The term is most frequently utilized in clinical pathology to describe amyotrophic lateral sclerosis, a severe condition that selectively destroys motor neurons, disrupting voluntary movement control.
• Amyotrophy — Atrophy or progressive decrease in the volume of muscle mass, caused by a nutritional disorder of the muscles or the loss of normal motor innervation. This pathological structural condition causes severe weakness of the skeletal muscles and is frequently associated with lesions of the spinal cord or peripheral nerves.
• Anatrofion — A pharmaceutical preparation, nutritional supplement, or biological substance with tonic, fortifying, and regenerative properties, historically used to combat malnutrition, physical weakness, or progressive muscular atrophy. This structural compound stimulates cellular metabolic processes of assimilation, favoring the rapid recovery of degraded tissues and restoring the vital strength of a convalescent organism.
• Stiffening process — The act of becoming ankylosed and its result; the pathophysiological process or state through which a joint gradually or totally loses its mobility, becoming rigid due to fibrous or bony transformations.